Participated · Seed · Apr 2026

Iteria Biopharma was founded in 2024 and is headquartered in Touro (A Coruña); its leadership team includes co-founders from GalChimia, Julio Castro (Palobiofarma) and CEO Ramon Bosser. The company’s lead asset is ITR-251, a novel molecule targeting metastatic castration-resistant prostate cancer, and it also runs two early research programs aimed at pancreatic, colorectal and lung cancers. Iteria uses unconventional medicinal chemistry approaches to discover candidates for cancers where existing therapies fail. Following the €5 million Series Seed round, the company plans to complete regulatory preclinical work and initiate a Phase 1 trial for ITR-251 in early 2027. The funding will also support identification and preclinical progression of candidates in its two other oncology programs over the next two years. Iteria has previously been supported by founders’ capital and public grants from MICINN and CDTI."}

Participated · Seed · Mar 2026

Founded in 2019 by Iván García Besada and Roberto Estévez Quintela, Néboda has built its own vertical-indoor agriculture system that combines hydroponics, robotics and artificial intelligence to optimize every stage of leafy-green and aromatic-herb cultivation. The platform delivers pesticide-free, flavorful and longer-lasting produce at costs competitive with traditional agriculture. Over the last three years the company has quadrupled yield per square meter, cut water use by more than 90 %, and minimized its environmental footprint. Néboda currently operates a 200 m² pre-industrial plant in Galicia with an annual capacity of 8,000 kg, selling all output through leading Iberian fresh-produce distributors. The system is designed to be easily replicated worldwide, enabling local production and lower logistics costs. With the new funding, the firm will validate key business metrics, secure additional sales agreements and prepare for a planned Series A in 2026 to build its first full-scale industrial facility.

Participated · Seed · Dec 2025

Batea Oncology is developing a mechanomedicine platform that applies the mechanical properties of cancer cells to trap and alter residual tumor cells after surgery, beginning with glioblastoma. Its lead product, GlioHook, is a Class III implantable polycarbonate–polyurethane scaffold coated with bovine collagen designed to be stiffer than brain tissue so infiltrating tumor cells migrate into and adhere within the device. Mechanical confinement within GlioHook is claimed to reduce DNA repair and adaptive resistance pathways, increasing tumor-cell sensitivity to radiotherapy. The company has finalized GMP manufacturing, completed its regulatory preclinical package, and received Ethics Committee clearance for a first-in-human trial of 15 newly diagnosed glioblastoma patients with enrollment expected in Q4 2026. Batea plans to expand its mechanomedicine approach beyond glioblastoma to other solid tumors with high recurrence such as soft tissue sarcoma and is investigating combinations with immunotherapies. The company is based in Santiago de Compostela and has raised more than €3.1 million to date while currently closing an €8.5 million Series A to support clinical development and regulatory progression.

Participated · Equity · Dec 2025

BioflyTech specializes in breeding and processing the black soldier fly to obtain high-protein ingredients for pet food and aquaculture feed. The company currently operates a facility in Palas de Rei capable of producing about 12,000 t of insect-based product per year. It plans a major plant expansion, recently declared a Strategic Industrial Project (PIE) by the Xunta de Galicia, which will invest more than €100 M to lift capacity to 62,000 t annually. The enlargement is expected to create roughly 150 direct and indirect jobs. To support the commercial launch of its product portfolio and prepare for this scale-up, BioflyTech has secured a €4 M equity infusion from existing investors. The firm’s backers include CDTI-Innvierte, Xesgalicia, and Moira Capital. This latest financing fully covers the amount sought in the round, reinforcing BioflyTech’s balance sheet ahead of the expansion.

Led · Equity · Dec 2025

Founded in 2022 in Galicia, Vig-Sec Drone builds Suite ACRE (Área de Control Restringido de Emergencias), an Emergency UTM system with dual civil and military use that can monitor and reconfigure airspace on the fly, fusing data from manned aircraft, drones and terrestrial or maritime sensors into a single operational view. The platform has already been validated with Spanish Ministry of Defense helicopters, deployed in multinational exercises in Slovakia with the BRILAT brigade and selected for the ATLAS 25 exercise to manage simultaneous manned and unmanned flights. Vig-Sec Drone is aligning its technology with NATO and EASA standards and has been invited to the Spanish Army’s Fuerza 2035 program, underscoring its strategic defense relevance. The company has expanded from its two founders to more than 17 professionals and operates out of Lugo and Nigrán. Fresh capital will accelerate AI-driven automation and support international rollout of Suite ACRE. To date, the firm has secured €1 million in external funding.